A fast-changing Merck KGaA is backing away from discovery and preclinical R&D deals it set up with the antibody specialists at Ablynx. And the Belgian biotech saw its shares slide 14% today after news of the prospective breakup–included in Ablynx’s annual summary–spread in the markets.

…read more

Source: Ablynx gets caught in Merck KGaA’s R&D retreat


0 No comments